Pulmatrix

July 24, 2015November 6, 2015

Pulmatrix Acquires Two More Patents for iSPERSE Technology For Pulmonary Disease Treatments

Asthma, News

Pulmatrix, Inc., a clinical stage biopharmaceutical company focused on developing inhaled therapies to address serious pulmonary diseases, has announced the award of 2 new patents (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352) from the ... Read more

June 17, 2015November 9, 2015

Pulmatrix And Mylan Enter Enter Into Agreement To Develop PUR0200, iSPERSE COPD Therapies

COPD, News

Pulmatrix, a clinical stage bio-pharmaceutical firm advancing innovative therapies via inhalation to address serious pulmonary diseases, has recently announced it has entered into a partnership with Mylan N.V., which is a leading worldwide global pharmaceutical company. ... Read more